CT-163 Outcomes of Hematological Malignancy Patients Who Underwent Haploidentical SC Transplant With ATG of 2 Mg/kg Based Conditioning Regimen

MLA

Momen Nassani, et al. “CT-163 Outcomes of Hematological Malignancy Patients Who Underwent Haploidentical SC Transplant With ATG of 2 Mg/Kg Based Conditioning Regimen.” Clinical Lymphoma Myeloma and Leukemia, vol. 22, Oct. 2022, p. S436. EBSCOhost, https://doi.org/10.1016/s2152-2650(22)01651-2.

APA

Momen Nassani, Walid Rasheed, Majed Altareb, Ali Alsharif, Feras Alfraih, Amr Hanbali, Saud Alhayli, Syed Osman Ahmed, Abdulwahab A. Albabtain, Marwan Shaheen, Naeem Chaudhri, Fahad Alsharif, Alfadel Alshaibani, Ahmad S. Alotaibi, Tusneem Elhassan, Fahad Almohareb, Ali Alahmari, Hazzaa Alzahrani, Mahmoud Aljurf, & Riad El Fakih. (2022). CT-163 Outcomes of Hematological Malignancy Patients Who Underwent Haploidentical SC Transplant With ATG of 2 Mg/kg Based Conditioning Regimen. Clinical Lymphoma Myeloma and Leukemia, 22, S436. https://doi.org/10.1016/s2152-2650(22)01651-2

Chicago

Momen Nassani, Walid Rasheed, Majed Altareb, Ali Alsharif, Feras Alfraih, Amr Hanbali, Saud Alhayli, et al. 2022. “CT-163 Outcomes of Hematological Malignancy Patients Who Underwent Haploidentical SC Transplant With ATG of 2 Mg/Kg Based Conditioning Regimen.” Clinical Lymphoma Myeloma and Leukemia 22 (October): S436. doi:10.1016/s2152-2650(22)01651-2.